ELANElanco Animal Health Inc
Pharmaceutical Preparations
- Revenue
- $4.7B
- 6.2% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $3.3B net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear1% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear36% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $4.8B | $4.4B | $4.4B | $4.4B | $4.7B | 6.2% |
| Net income | −$483M | −$78M | −$1.2B | $338M | −$232M | 169% |
| Operating cash flow | $483M | $452M | $271M | $541M | $560M | 3.5% |
| Capex | $159M | $171M | $140M | $147M | $276M | 88% |
| Stock-based comp | $66M | $59M | $46M | $55M | $68M | 24% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $100K · 1
- Net
- −$100K
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $15M | $38M | 74 | 188 |
| FY2024 | $15M | $9M | 39 | 148 |
| FY2023 | $14M | $17M | 49 | 137 |
| FY2022 | $13M | −$2M | 40 | 136 |
| FY2021 | $12M | $17M | 93 | 126 |